Study Summary
Evaluate the safety, pharmacokinetic (PK) characteristics, and pharmacodynamic (PD) characteristics of LV009 injection in subjects with relapsed/refractory CD19-positive hematologic malignancies.
Want to learn more about this trial?
Request More InfoInterventions
LV009 Injection InfusionBIOLOGICAL
A dose escalation was conducted using four fixed doses of LV009 injection solution: 0.3 × 10\^9, 0.6 × 10\^9, 1.2 × 10\^9, and 2.4 × 10\^9 TU.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| PersonGen.Anke Cellular Therapeutice Co., Ltd. | Hefei | Anhui | China |